CNS Pharmaceuticals (CNSP) EPS (Basic) (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly EPS (Basic) came in at -$13.51 in Q4 2025, up 86.56% YoY from -$7.24 in Q4 2024, and down 131.88% on a QoQ basis from -$5.83 in Q3 2025.
CNS Pharmaceuticals (CNSP) EPS (Basic) (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of EPS (Basic) data on file, last reported at -$13.51 in Q4 2025.
- Quarterly EPS (Basic) rose 86.56% year-over-year to -$13.51 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$36.09 (up 92.29% YoY) and the FY2025 annual result came in at -$78.51, up 91.72% from the prior year.
- EPS (Basic) retreated to -$13.51 in Q4 2025, from -$5.83 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$5.83 in Q3 2025 to a low of -$136202.6 in Q2 2021.
- A 5-year average of -$52810.7 and a median of -$37682.5 in 2023 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2021 — EPS (Basic) fell 22.41% — and 2025, when it jumped 99.84%.
- Tracing CNSP's EPS (Basic) over 5 years: stood at -$112210.5 in 2021, then slipped by 1.75% to -$114176.0 in 2022, then soared by 62.59% to -$42716.3 in 2023, then surged by 99.76% to -$100.47 in 2024, then surged by 86.56% to -$13.51 in 2025.
- The last three EPS (Basic) figures came in at -$13.51 (Q4 2025), -$5.83 (Q3 2025), and -$6.52 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.18 |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | -13.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13.51 |
| Sep 30, 2025 | -5.83 |
| Jun 30, 2025 | -6.52 |
| Mar 31, 2025 | -19.12 |
| Dec 31, 2024 | -100.47 |
| Sep 30, 2024 | -152.33 |
| Jun 30, 2024 | -4,032.80 |
| Mar 31, 2024 | -12,246.48 |
| Dec 31, 2023 | -42,716.29 |
| Sep 30, 2023 | -32,648.62 |
| Jun 30, 2023 | -31,563.05 |
| Mar 31, 2023 | -77,061.67 |
| Dec 31, 2022 | -114,175.96 |
| Sep 30, 2022 | -77,717.11 |
| Jun 30, 2022 | -81,044.36 |
| Mar 31, 2022 | -73,304.53 |
| Dec 31, 2021 | -112,210.48 |
| Sep 30, 2021 | -127,144.93 |
| Jun 30, 2021 | -136,202.61 |
| Mar 31, 2021 | -133,846.85 |